[Estimated impact of the current colorectal screening program in France].
Fiche publication
Date publication
mai 2020
Journal
Revue d'epidemiologie et de sante publique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GENDRE Isabelle
Tous les auteurs :
Barré S, Leleu H, Vimont A, Kaufmanis A, Gendre I, Taleb S, De Bels F
Lien Pubmed
Résumé
Colorectal cancer is the third most common cancer and the second most deadly in France. A Cochrane meta-analysis has confirmed the benefits of colorectal cancer screening. A nationwide colorectal screening program was set up in France in 2009 for medium-risk, asymptomatic people aged 50 to 74 years. It has been based, since 2015, on the Fecal Immunochemical Test. The participation rate for 2016-2017 was 34%, which is lower than the European objectives. The objective of this study was to evaluate the impact of the program at the current participation rate and at rates of 45% and 65%.
Mots clés
Cancer colorectal, Colorectal cancer, Dépistage collectif, Dépistage de masse, Mass screening, Program effectiveness, Évaluation d’un programme
Référence
Rev Epidemiol Sante Publique. 2020 May 13;: